Diagnosis and treatment of cutaneous melanoma: state of the art 2006*
Top Cited Papers
- 1 April 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 17 (2) , 117-127
- https://doi.org/10.1097/cmr.0b013e328042bb36
Abstract
Although the incidence of melanoma is still rising in Caucasian populations, the increase in mortality has leveled off. Improvements in early diagnosis, with more frequent diagnosis of low-risk patients (i.e. those with <1 mm of tumor thickness), is the main reason for these divergent developments. Primary prevention has not yet been successful and recent studies have demonstrated the lack of effectiveness of sunscreen in preventing nevi in children. Progress was made in early melanoma diagnosis when dermoscopy and digital dermoscopy were introduced, and computer algorithms have proved to be highly efficacious for automated melanoma diagnosis. Primary melanomas are now excised with narrower surgical margins of 1-2 cm. Sentinel-node biopsy is recommended as a nodal staging procedure in patients with tumor thickness of 1 mm and more, but the prognostic impact of this procedure has not yet been demonstrated. New imaging techniques, e.g. whole-body MRI and PET-CT, provide more accurate staging, particularly in patients with apparent metastasis, and facilitate decisions on surgical treatment strategies. Staging is now based on the 2001 TNM classification including tumor thickness and histopathologic ulceration in stages I and II and lymph node micro and macro-metastasis in stage III. A stage- and risk-adopted follow-up schedule is proposed for melanoma surveillance. Adjuvant therapy with interferon-alpha in high-risk patients offers a small benefit in terms of recurrence-free and overall survival; the optimal dosage and duration of this treatment are still to be defined. Almost no progress has been made in the medical treatment of disseminated metastasis of melanoma. Therapy with dacarbazine and a few other single agents remains the first-line treatment approach of choice. A number of new treatment modalities, including targeted molecules and immunologic approaches with monoclonal antibodies, are under development; hopefully, new treatment modalities will be available in the near future.Keywords
This publication has 94 references indexed in Scilit:
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006
- Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanomaEuropean Journal Of Cancer, 2006
- Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patientsEuropean Journal Of Cancer, 2004
- Excision Margins in High-Risk Malignant MelanomaNew England Journal of Medicine, 2004
- Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in ScandinaviaInternational Journal of Cancer, 2003
- Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhoodCancer, 2003
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Thin Stage I Primary Cutaneous Malignant MelanomaNew England Journal of Medicine, 1988
- In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesionsJournal of the American Academy of Dermatology, 1987
- Number of melanocytic nevi as a major risk factor for malignant melanomaJournal of the American Academy of Dermatology, 1987